Natarajan Prabitha, Liu Dong, Patel Seema R, Santhanakrishnan Manjula, Beitler Daniel, Liu Jingchun, Gibb David R, Liepkalns Justine S, Madrid David J, Eisenbarth Stephanie C, Stowell Sean R, Hendrickson Jeanne E
Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, United States.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, United States.
Front Immunol. 2017 Aug 7;8:907. doi: 10.3389/fimmu.2017.00907. eCollection 2017.
Approximately 3-10% of human red blood cell (RBC) transfusion recipients form alloantibodies to non-self, non-ABO blood group antigens expressed on donor RBCs, with these alloantibodies having the potential to be clinically significant in transfusion and pregnancy settings. However, the majority of transfused individuals never form detectable alloantibodies. Expanding upon observations that children initially transfused with RBCs at a young age are less likely to form alloantibodies throughout their lives, we hypothesized that "non-responders" may not only be ignorant of antigens on RBCs but instead tolerized. We investigated this question in a reductionist murine model, in which transgenic donors express the human glycophorin A (hGPA) antigen in an RBC-specific manner. Although wild-type mice treated with poly IC and transfused with hGPA RBCs generated robust anti-hGPA IgG alloantibodies that led to rapid clearance of incompatible RBCs, those transfused in the absence of an adjuvant failed to become alloimmunized. Animals depleted of CD4 cells or treated with CD40L blockade prior to initial hGPA RBC exposure, in the presence of poly IC, failed to generate detectable anti-hGPA IgG alloantibodies. These non-responders to a primary transfusion remained unable to generate anti-hGPA IgG alloantibodies upon secondary hGPA exposure and did not prematurely clear transfused hGPA RBCs even after their CD4 cells had returned or their CD40L blockade had resolved. This observed tolerance was antigen (hGPA) specific, as robust IgG responses to transfused RBCs expressing a third-party antigen occurred in all studied groups. Experiments completed in an RBC alloimmunization model that allowed evaluation of antigen-specific CD4 T-cells (HOD (hen egg lysozyme, ovalbumin, and human duffy)) demonstrated that CD40L blockade prevented the expansion of ovalbumin 323-339 specific T-cells after HOD RBC transfusion and also prevented germinal center formation. Taken together, our data suggest that recipients may indeed become tolerized to antigens expressed on RBCs, with the recipient's immune status upon initial RBC exposure dictating future responses. Although questions surrounding mechanism(s) and sustainability of tolerance remain, these data lay the groundwork for future work investigating RBC immunity versus tolerance in reductionist models and in humans.
大约3%至10%的人类红细胞(RBC)输血受者会针对供体红细胞上表达的非自身、非ABO血型抗原形成同种抗体,这些同种抗体在输血和妊娠情况下可能具有临床意义。然而,大多数输血个体从未形成可检测到的同种抗体。基于儿童在幼年时首次输注红细胞后一生中形成同种抗体的可能性较小这一观察结果,我们推测“无反应者”可能不仅对红细胞上的抗原无知,而且处于耐受状态。我们在一个简化的小鼠模型中研究了这个问题,在该模型中,转基因供体以红细胞特异性方式表达人类血型糖蛋白A(hGPA)抗原。尽管用聚肌胞苷酸(poly IC)处理并输注hGPA红细胞的野生型小鼠产生了强大的抗hGPA IgG同种抗体,导致不相容红细胞迅速清除,但在没有佐剂的情况下输注的小鼠未能产生同种免疫。在初次接触hGPA红细胞之前,用聚肌胞苷酸处理并耗尽CD4细胞或用CD40L阻断剂处理的动物未能产生可检测到的抗hGPA IgG同种抗体。这些对初次输血无反应的动物在再次接触hGPA后仍无法产生抗hGPA IgG同种抗体,即使在其CD4细胞恢复或CD40L阻断解除后,也不会过早清除输注的hGPA红细胞。观察到的这种耐受性是抗原(hGPA)特异性的,因为在所有研究组中,对表达第三方抗原的输注红细胞都出现了强烈的IgG反应。在一个允许评估抗原特异性CD4 T细胞(HOD(鸡蛋溶菌酶、卵清蛋白和人类达菲))的红细胞同种免疫模型中完成的实验表明,CD40L阻断可防止HOD红细胞输血后卵清蛋白323 - 339特异性T细胞的扩增,也可防止生发中心的形成。综上所述,我们的数据表明,受者确实可能对红细胞上表达的抗原产生耐受,初次接触红细胞时受者的免疫状态决定了其未来的反应。尽管围绕耐受性的机制和可持续性仍存在问题,但这些数据为未来在简化模型和人类中研究红细胞免疫与耐受的工作奠定了基础。